Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Response-adapted treatment with mosunetuzumab with or without obinutuzumab and polatuzumab vedotin in treatment naïve follicular and marginal zone lymphoma: Final results and phased-seq MRD analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

CPChristina PohCUChaitra S. UjjaniVRVikram Raghunathan

Discussion

Loading...

Member takes

Overview

Single-center trial demonstrates complete response in 90% of treatment-naive follicular lymphoma patients, indicating potential for chemo-free treatment.

Key Points

  • High complete response rates were achieved with mosunetuzumab in treating follicular lymphoma and marginal zone lymphoma.
  • The study indicates a 90% best response rate with 2-year progression-free survival at 88% for enrolled patients.
  • Patients underwent a response-adapted treatment protocol, with analysis of minimal residual disease over the treatment timeline.
  • Results suggest that MRD-adapted strategies may help tailor therapy intensity based on treatment response and disease status.

Cite This Study

Poh et al. (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d9e4https://doi.org/10.1182/blood-2025-3591
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: A multicenter Phase 2 trial2025 · 1 citations
  2. 2Fixed-duration subcutaneous mosunetuzumab demonstrates sustained clinically meaningful outcomes in patients with previously untreated, low-tumor burden follicular lymphoma2025
  3. 3Fixed treatment duration mosunetuzumab continues to demonstrate clinically meaningful outcomes in patients with relapsed/refractory (R/R) follicular lymphoma (FL) after ≥2 prior therapies: 5-year follow-up of a pivotal Phase II study2025
  4. 4Fixed-duration subcutaneous mosunetuzumab continues to demonstrate high rates of durable responses in patients with relapsed/refractory follicular lymphoma after ≥2 prior therapies: 3-year follow-up from a pivotal Phase II study2025 · 1 citations
  5. 5Real-world outcomes of mosunetuzumab use in indolent and aggressive lymphomas2025 · 1 citations